Chen Z, et al. (2023) Phosphomevalonate Kinase Controls β-Catenin Signaling via the Metabolite 5-Diphosphomevalonate. Adv Sci (Weinh) 10, e2204909 36808719

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T41-p - CTNNB1 (human) ▲
Modsite: GIHsGATtTAPsLsG SwissProt Entrez-Gene Orthologous residues CTNNB1 (human): T41‑p, CTNNB1 (mouse): T41‑p, CTNNB1 (rat): T41‑p, CTNNB1 (rabbit): T41‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human

S45-p - CTNNB1 (human) ▲

Modsite: GATtTAPsLsGkGNP SwissProt Entrez-Gene Orthologous residues CTNNB1 (human): S45‑p, CTNNB1 (mouse): S45‑p, CTNNB1 (rat): S45‑p, CTNNB1 (rabbit): S45‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK1A (human) KINASE GSK3B (human) Downstream Regulation Effect of modification (function):  protein degradation

S184-p - CTNNB1 (human) ▲

Modsite: QLskKEAsRHAIMRs SwissProt Entrez-Gene Orthologous residues CTNNB1 (human): S184‑p, CTNNB1 (mouse): S184‑p, CTNNB1 (rat): S184‑p, CTNNB1 (rabbit): S184‑p Characterization Methods used to characterize site in vivo:  immunoassay, mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  liver cancer, hepatocellular carcinoma Relevant cell lines - cell types - tissues:  293 (epithelial), embryo, Hep3B (hepatic), Huh7 (hepatic), liver Cellular systems studied:  cell lines, tissue Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE PMVK (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PMVK (human) co-immunoprecipitation, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes mevalonate 5-diphosphate increase mevalonate 5-phosphate increase methyl-beta-cyclodextrin increase PMVKi5 decrease Downstream Regulation Effect of modification (function):  intracellular localization, molecular association, regulation, phosphorylation, protein stabilization Effect of modification (process):  carcinogenesis, induced, signaling pathway regulation, transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays GSK3B (human) Disrupts co-immunoprecipitation BTRC (human) Disrupts co-immunoprecipitation CK1A (human) Disrupts co-immunoprecipitation Comments:  inhibits phosphorylation at Thr41 and Ser45 and ubiquitination, induces ß-catenin downstream signaling Associated Diseases Diseases Alterations Comments hepatocellular carcinoma increased